Susceptibility of Oka varicella vaccine strain to antiviral drugs

Shiraki, Kimíyasu; Matsui, Shoko; Aiba, Nobuyasu

doi:10.1016/0264-410x(93)90164-s

Cited by 10 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VZV foci were isolated by cylinder cloning of infected cells and propagated in 25 cm 2 plastic¯asks. A portion of the infected cells were subjected to sorivudine [Machida, 1986;Shiraki et al, 1993] resistance and immuno¯uor-escence to gp120 using anti-gp120 monoclonal antibody (ABI, MD), and then selected as the candidate to clone. The presence of the HIVenv gene was con®rmed by PCR detection of the HIVenv sequence in the genome using the two primers comprising the HIVenv sequence [Adachi et al, 1986] (5 H end, 7172-ATAGGAAAAAT-AGGAAATATGAGACAAG-7199, 5…”

Section: Construction Of a Recombinant Oka Varicella Vaccine Strainmentioning

confidence: 99%

Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen

Shiraki

Sato

Yoshida

et al. 2001

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Oka varicella vaccine has been used to confer active immunity to varicella-zoster virus (VZV) in healthy and immunocompromised hosts. Based on its attenuated nature, Oka varicella vaccine expressing human immunodeficiency virus (HIV) env antigen was constructed by inserting the HIVenv gene into the viral genome and its immunogenicity was assessed in guinea pigs. The HIVenv gene encoding 296-463 amino acids was inserted between the sequences of the hepatitis B surface antigen and the thymidine kinase gene of the cloned plasmid and the recombinant virus was isolated by cotransfection of the chimeric plasmid with viral DNA. Insertion of the HIVenv gene into the viral genome was confirmed by PCR and sequencing of the viral genome of the recombinant virus. The recombinant virus expressed 30k HIVenv fusion protein in its infected cells. In guinea pigs, immunization with the recombinant virus induced an antibody response to both the HIV antigen and the V3 peptide of gp120 as well as VZV gE:gI. Cell-mediated immunity to the HIV antigen and gE:gI was assessed by the cutaneous reaction representing delayed type hypersensitivity. Immunized guinea pigs responded well to both the HIV antigen and gE:gI. Thus the recombinant Oka varicella vaccine expressing the HIVenv antigen induced both a humoral and cell-mediated immunity to the HIV antigen similar to VZV as Oka varicella vaccine induces humoral and cell-mediated immunity to VZV in the vaccinees. This recombinant Oka varicella vaccine expressing the HIVenv antigen may be evaluated for its immunogenicity as one of the AIDS vaccine candidates.

show abstract

Section: Construction Of a Recombinant Oka Varicella Vaccine Strainmentioning

confidence: 99%

Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen

Shiraki

Sato

Yoshida

et al. 2001

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Oka vaccine strain of VZV the was attenuated by serial passages in cell cultures rendering it avirulant as compared to wild type strains and is susceptible to standard antivirals[31]. Antivirals have been shown to reduce the duration of the skin lesions of HZ by only 1–2 days[32].…”

Section: Introductionmentioning

confidence: 99%

The case for Zostavax vaccination in systemic lupus erythematosus

Cogman

Chakravarty

2013

Vaccine

View full text Add to dashboard Cite

“…[26][27][28][29] Vaccine-strain VZV has been shown to have similar susceptibility to antivirals as wild-type virus. 30 Acyclovir-resistant vaccine-strain VZV has been reported in 2 cases among children who were both diagnosed with neuroblastoma and received chemotherapy within 1 week after varicella vaccination. 8,12 Both patients had lesions that became verrucous despite prolonged acyclovir treatment (approximately 7 mo and 5 weeks, respectively).…”

mentioning

confidence: 99%